Pramiconazole

{{Drugbox | verifiedrevid = 366890982 | IUPAC_name = 1-{4-[4-(4-{[(2R,4S)-2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one | image = Pramiconazole.png | width = | image2 = | width2 = | imagename = | drug_name = | CAS_number = | CAS_supplemental = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = 11411233 | DrugBank = | chemical_formula = | C=35 | H=39 | F=2 | N=7 | O=4 | molecular_weight = 659.725 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}

Pramiconazole is a triazole antifungal undergoing research for the treatment of acute skin and mucosal fungal infections.

It is developed by Barrier Therapeutics.